Grufity logo
Grufity logo

Latest Eversept Partners, LP Stock Portfolio

$1.90Billion | No. of Holdings #105

Eversept Partners, LP Performance

2026 Q1-3.42%
YTD-3.42%
2025+19.86%

About Eversept Partners, LP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Eversept Partners, LP reported an equity portfolio of $1.9 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Eversept Partners, LP are UTHR, , GSK. The fund has invested 8.3% of it's portfolio in UNITED THERAPEUTICS CORP DEL and 5.5% of portfolio in ABIVAX SA. <br><br> The fund managers got completely rid off DANAHER CORPORATION (DHR), EXACT SCIENCES CORP (EXAS) and CIDARA THERAPEUTICS INC (CDTX) stocks. They significantly reduced their stock positions in TYRA BIOSCIENCES INC (TYRA), BRUKER CORP (BRKR) and ULTRAGENYX PHARMACEUTICAL IN (RARE). Eversept Partners, LP opened new stock positions in WELLTOWER INC (WELL), HEALTHPEAK PROPERTIES INC (PEAK) and OMEGA HEALTHCARE INVS INC (OHI). The fund showed a lot of confidence in some stocks as they added substantially to BROOKDALE SR LIVING INC (BKD), SAVARA INC (SVRA) and BIOMARIN PHARMACEUTICAL INC (BMRN).
Eversept Partners, LP Equity Portfolio Value
Last Reported on: 15 May, 2026
$1.90Billion
  as of May 15, 2026

Eversept Partners, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Eversept Partners, LP made a return of -3.42% in the last quarter. In trailing 12 months, it's portfolio return was 27.61%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
welltower inc35,776,200
healthpeak properties inc32,549,000
omega healthcare invs inc25,664,500
qiagen nv21,835,000
repligen corp14,230,900
ltc pptys inc11,930,100
chemed corp new11,731,500
viking therapeutics inc7,780,640
New stocks bought by Eversept Partners, LP

Additions

Ticker% Inc.
brookdale sr living inc851
savara inc125
biomarin pharmaceutical inc121
beta bionics inc108
insulet corp92.14
encompass health corp81.53
eli lilly & co78.86
ss innovations international46.18
Additions to existing portfolio by Eversept Partners, LP

Reductions

Ticker% Reduced
tyra biosciences inc-90.29
bruker corp-85.07
ultragenyx pharmaceutical in-80.27
anaptysbio inc-77.6
assembly biosciences inc-74.39
healthequity inc-72.21
bio-techne corp-66.64
bioventus inc-66.24
Eversept Partners, LP reduced stake in above stock

Sold off

Ticker$ Sold
mannkind corp-10,504,000
select med hldgs corp-13,455,600
maravai lifesciences hldgs i-2,335,390
teva pharmaceutical inds ltd-20,604,100
dynavax technologies corp-9,319,910
catalyst pharmaceuticals inc-8,359,640
evolus inc-2,288,290
edgewise therapeutics inc-8,371,090
Eversept Partners, LP got rid off the above stocks

Sector Distribution

Eversept Partners, LP has about 71% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
  • Real Estate
  • Basic Materials
Sector%
Healthcare71
Others20.1
Real Estate7
Basic Materials1.5

Market Cap. Distribution

Eversept Partners, LP has about 32.3% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • SMALL-CAP
  • UNALLOCATED
  • MICRO-CAP
  • MEGA-CAP
Category%
LARGE-CAP31.1
MID-CAP23.2
SMALL-CAP22.1
UNALLOCATED20.1
MICRO-CAP2
MEGA-CAP1.2

Stocks belong to which Index?

About 49.3% of the stocks held by Eversept Partners, LP either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
  • S&P 500
Index%
Others50.7
RUSSELL 200037.4
S&P 50011.9
Top 5 Winners (%)%
STRO
sutro biopharma inc
79.4 %
MRNA
moderna inc
57.7 %
EHAB
enhabit inc
51.3 %
AADI
whitehawk therapeutics inc
38.1 %
ALEC
alector inc
31.5 %
Top 5 Winners ($)$
UTHR
united therapeutics corp del
27.3 M
GSK
gsk plc
13.7 M
PCVX
vaxcyte inc
12.7 M
CLDX
celldex therapeutics inc new
7.3 M
SNDX
syndax pharmaceuticals inc
7.3 M
Top 5 Losers (%)%
EHTH
ehealth inc
-71.7 %
beta bionics inc
-60.1 %
SLQT
selectquote inc
-55.4 %
ADGI
invivyd inc
-46.6 %
BCYC
bicycle therapeutics plc
-33.8 %
Top 5 Losers ($)$
VERA
vera therapeutics inc
-27.3 M
beta bionics inc
-21.4 M
abivax sa
-18.7 M
VRDN
viridian therapeutics inc
-14.4 M
AVTR
avantor inc
-11.1 M

Eversept Partners, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Eversept Partners, LP

Eversept Partners, LP has 105 stocks in it's portfolio. About 42.1% of the portfolio is in top 10 stocks. VERA proved to be the most loss making stock for the portfolio. UTHR was the most profitable stock for Eversept Partners, LP last quarter.

$1.52BTotal Value
134Positions
15 May, 2026Last Reported
Current holdings of Current Stock Holdings of Eversept Partners, LP, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Eversept Partners, LP's holding in Ascendis Pharma A/S over time
0%0.00
$0.00
0%
decreased 100 percentsold off